Showing 141-160 of 753 for: Cochrane Systematic Reviews > Pharmacotherapeutics 
- Beclomethasone for asthma in children: effects on linear growth
Cochrane Systematic Reviews, 25-Jul-2011
Inhaled steroids play a central role in the management of childhood asthma. There is concern about their side effects, especially on growth. However asthma may also cause growth retardation. Growth rates are not stable, so randomised controlled parallel g
- Behavioural and cognitive interventions with or without other treatments for the management of faecal incontinence in children
Cochrane Systematic Reviews, 9-Nov-2011
Faecal incontinence is a common and potentially distressing disorder of childhood.
- Benzodiazepine receptor antagonists for hepatic encephalopathy
Cochrane Systematic Reviews, 23-Sep-2008
Hepatic encephalopathy may be associated with accumulation of substances that bind to a receptor-complex in the brain resulting in neural inhibition. Benzodiazepine receptor antagonists may have a beneficial effect on patients with hepatic encephalopathy.
- Benzodiazepines and related drugs for insomnia in palliative care
Cochrane Systematic Reviews, 22-Nov-2013
Insomnia, a subjective complaint of poor sleep and associated impairment in daytime function, is a common problem. Currently, benzodiazepines are the most used pharmacological treatment for this complaint. They are considered helpful for occasional short-
- Benzodiazepines for alcohol withdrawal
Cochrane Systematic Reviews, 14-Feb-2010
Alcohol abuse and dependence represents a serious health problem worldwide with social, interpersonal and legal interpolations. Benzodiazepines have been widely used for the treatment of alcohol withdrawal symptoms. Moreover it is unknown whether differen
- Benzodiazepines for neuroleptic-induced acute akathisia
Cochrane Systematic Reviews, 22-Oct-2008
Neuroleptic-induced akathisia is one of the most common and distressing early-onset adverse effects of antipsychotic drugs, being associated with poor compliance with treatment, and thus, ultimately, to an increase risk of relapse. This review assesses th
- Benzodiazepines for neuroleptic-induced tardive dyskinesia
Cochrane Systematic Reviews, 18-Jan-2012
Tardive dyskinesia (TD) is a disfiguring movement disorder, often of the orofacial region, frequently caused by the use of neuroleptic drugs. A wide range of strategies have been used to help manage tardive dyskinesia, and for those who are unable to have
- Benzodiazepines for psychosis-induced aggression or agitation
Cochrane Systematic Reviews, 26-Mar-2013
Acute psychotic illness, especially when associated with agitated or violent behaviour, can require urgent pharmacological tranquillisation or sedation. In several countries, clinicians often use benzodiazepines (either alone or in combination with antips
- Benzodiazepines for schizophrenia
Cochrane Systematic Reviews, 2-Oct-2012
Because of the high number of people with schizophrenia not responding adequately to monotherapy with antipsychotic agents, the evidence regarding the efficacy and safety of additional medication was examined in a number of clinical trials. One approach t
- Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis
Cochrane Systematic Reviews, 6-Jan-2014
Optimal antibiotic treatment for sepsis is imperative. Combining a beta lactam antibiotic with an aminoglycoside antibiotic may provide certain advantages over beta lactam monotherapy.
- Beta-blocker supplementation of standard drug treatment for schizophrenia
Cochrane Systematic Reviews, 15-Jun-2010
Many people with schizophrenia or similar severe mental disorders do not achieve a satisfactory treatment response with ordinary antipsychotic drug treatment. In these cases, various add-on medications are used, amongst them beta-adrenergic receptor antag
- Beta-blocker therapy for tremor in Parkinson's disease
Cochrane Systematic Reviews, 11-Nov-2008
The tremor of Parkinson's disease can cause considerable disability for the individual concerned. Traditional antiparkinsonian therapies such as levodopa have only a minor effect on tremor. Beta-blockers are used to attenuate other forms of tremor such as
- Beta-blockers for hypertension
Cochrane Systematic Reviews, 27-Aug-2012
This review is an update of the Cochrane Review published in 2007, which assessed the role of beta-blockade as first-line therapy for hypertension.
- Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia
Cochrane Systematic Reviews, 11-Feb-2015
Continued controversy surrounds the optimal empirical treatment for febrile neutropenia. New broad-spectrum beta-lactams have been introduced as single treatment, and classically, a combination of a beta-lactam with an aminoglycoside has been used.
- Bisphosphonate therapy for children and adolescents with secondary osteoporosis
Cochrane Systematic Reviews, 24-May-2010
Children with chronic illnesses are at increased risk for reductions in bone strength and subsequent fractures (osteoporosis), either due to the impact of the underlying condition on skeletal development or due to the osteotoxic effect of medications (e.g
- Bisphosphonates and other bone agents for breast cancer
Cochrane Systematic Reviews, 3-Jan-2012
Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast-mediated bone resorption, and novel targeted therapies such as denosumab, inhibit key pathways in the vicious cycle of bone metastase
- Bisphosphonates for advanced prostate cancer
Cochrane Systematic Reviews, 22-Nov-2009
Prostate cancer is the most common cancer in men in many western countries. It is characterized by its propensity for bone metastases which occur in more than 80% of patients with advanced disease. Patients are at risk of complications including pain, hyp
- Bisphosphonates for osteoporosis in people with cystic fibrosis
Cochrane Systematic Reviews, 13-Apr-2015
Osteoporosis is a bone mineralisation disorder occurring in about one third of adults with cystic fibrosis. Bisphosphonates can increase bone mineral density and decrease the risk of new fractures in post-menopausal women and people receiving long-term or
- Bisphosphonates for steroid induced osteoporosis
Cochrane Systematic Reviews, 24-May-2010
Corticosteroids are widely used in inflammatory conditions as an immunosuppressive agent. Diseases treated with corticosteroids include connective tissue diseases, asthma, inflammatory bowel disease and organ transplantation. Bone loss is a serious side e
- Bisphosphonates for the relief of pain secondary to bone metastases
Cochrane Systematic Reviews, 11-Aug-2009
Bisphosphonates form part of standard therapy for hypercalcemia and the prevention of skeletal events in some cancers. However, the role of bisphosphonates in pain relief for bony metastases remains uncertain.
